You are here: Industry Insights > yellow fever

News List

SLU Researchers Begin Enrolling Participants in Yellow Fever Vaccine Clinical Trial firstwordpharma
July 22, 2021
Saint Louis University's Center for Vaccine Development is studying an investigational vaccine for yellow fever, a potentially deadly disease that is spread by mosquitoes. The research is funded by Sanofi Pasteur.
KU Leuven vaccine candidate protects against COVID-19 and yellow fever worldpharmanews
December 04, 2020
Virologists at the Rega Institute at KU Leuven (Belgium) have developed a vaccine candidate against COVID-19 based on the yellow fever vaccine, which as a result also works against yellow fever.
WuXi Biologics Congratulates Tychan on Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers En-CPhI.CN
November 19, 2019
WuXi Biologics congratulates its partner Tychan on successful completion of the Phase 1A/1B safety and efficacy trials in Singapore for TY014, a first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF).
World's First Candidate Antibody Treatment for Yellow Fever, Developed by Tychan, Tested Safe and Effective in Human Volunteers En-CPhI.CN
November 15, 2019
Tychan's first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF), called TY014, has successfully completed Phase 1A/1B safety trials in Singapore, it announced.
Protection against yellow fever provided by fractional-dose vaccination europeanpharmaceuticalreview
November 28, 2018
Researchers at Leiden University Medical Center have identified how fractional-dose yellow fever vaccinations protect against the condition for ten years…
WHO supports the immunization of people against yellow fever in Nigeria biospectrumasia
October 18, 2017
The ten-day campaign was started on Friday, 13 October 2017, and mobilizes more than 200 health workers and volunteers. It targets residents aged 9 months to 45 years old
KU Leuven to develop dual vaccine against yellow fever and rabies financialexpress
April 06, 2017
The RABYD-VAX consortium, led by KU Leuven (University of Leuven, Belgium), has started developing a cheap, temperature-stable, and easy-to-produce vaccine against both diseases at once